Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biocept Inc (BIOC)

Biocept Inc (BIOC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,818
  • Shares Outstanding, K 13,403
  • Annual Sales, $ 27,460 K
  • Annual Income, $ -17,810 K
  • 60-Month Beta 0.81
  • Price/Sales 1.91
  • Price/Cash Flow N/A
  • Price/Book 1.96
Trade BIOC with:

Options Overview

Details
  • Implied Volatility 140.71%
  • Historical Volatility 47.88%
  • IV Percentile 31%
  • IV Rank 7.57%
  • IV High 689.37% on 03/31/21
  • IV Low 95.76% on 05/10/21
  • Put/Call Vol Ratio 0.18
  • Today's Volume 150
  • Volume Avg (30-Day) 137
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 2,768
  • Open Int (30-Day) 4,635

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +124,975.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.63 +8.82%
on 07/19/21
4.25 -7.06%
on 07/21/21
-0.26 (-6.18%)
since 07/02/21
3-Month
3.63 +8.82%
on 07/19/21
4.97 -20.52%
on 06/22/21
-0.74 (-15.78%)
since 05/03/21
52-Week
3.46 +14.16%
on 09/11/20
13.00 -69.62%
on 08/06/20
-3.66 (-48.09%)
since 08/03/20

Most Recent Stories

More News
Biocept Names David Karlander as Senior Vice President of Commercial Operations

Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed David Karlander as Senior Vice President of Commercial Operations. With more than 25 years...

BIOC : 3.95 (-3.66%)
Circulating Tumor Cells Market will generate massive revenue by 2028 according to forecasts by Report Ocean

The global size is expected to reach USD 29.05 Billion by 2028 according to a new study by . Worldwide Circulating Tumor Cells Market Analysis, 2021 research report portrays a profound plunge of market...

BIOC : 3.95 (-3.66%)
SSMXY : 61.5400 (+2.22%)
Medicare Issues Local Coverage Determination for Biocept's Target Selector(TM) Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

--Company provides updates on other initiatives including CNSide(TM), its proprietary test for neuro-oncology, and COVID-19 testing volume, which has now reached over 450,000 samples

BIOC : 3.95 (-3.66%)
Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman

Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Linda Rubinstein and Antonino Morales to its Board of Directors, effective immediately. The...

BIOC : 3.95 (-3.66%)
Biocept to Participate in Two July Investment Conferences

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will participate at the following investment conferences:...

BIOC : 3.95 (-3.66%)
Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers

Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular diagnostic assays and services, has been awarded a South Korean Patent for its Primer-Switch technology, which detects rare mutations in circulating...

BIOC : 3.95 (-3.66%)
Biocept Joins the Russell Microcap(R) Index

Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will be added to the Russell Microcap Index after the U.S. market opens today, June 28,...

BIOC : 3.95 (-3.66%)
Thinking about buying stock in Biocept, Histogen, Idera Pharmaceuticals, Satsuma Pharmaceuticals, or Clover Health Investments?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, HSTO, IDRA, STSA, and CLOV.

CLOV : 8.12 (-0.37%)
HSTO : 0.8503 (-4.46%)
STSA : 4.98 (-5.32%)
BIOC : 3.95 (-3.66%)
IDRA : 1.1100 (+5.71%)
Biocept to Collaborate with Quest Diagnostics to Provide Advanced NGS-Based Liquid Biopsy Testing for Patients with Lung Cancer

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced a collaboration with Quest Diagnostics (NYSE: DGX) to provide laboratory testing...

BIOC : 3.95 (-3.66%)
DGX : 145.36 (+1.62%)
Biocept Receives More Than 420,000 Samples During First Year of Offering COVID-19 Testing Service

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it has received more than 420,000 samples for SARS-CoV-2 testing since launching this...

BIOC : 3.95 (-3.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept,...

See More

Key Turning Points

3rd Resistance Point 4.28
2nd Resistance Point 4.21
1st Resistance Point 4.08
Last Price 3.95
1st Support Level 3.88
2nd Support Level 3.81
3rd Support Level 3.68

See More

52-Week High 13.00
Fibonacci 61.8% 9.36
Fibonacci 50% 8.23
Fibonacci 38.2% 7.10
Last Price 3.95
52-Week Low 3.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar